Astellas and Pfizer seek to expand Xtandi’s patient base with another prostate cancer victory after 8 years – FiercePharma

  1. Astellas and Pfizer seek to expand Xtandi’s patient base with another prostate cancer victory after 8 yearsFiercePharma
  2. Pfizer and Astellas seek expanded label for expensive prostate cancer drugBioSpace
  3. Enzalutamide plus leuprolide boosts metastasis-free survival in nmHSPCUrology time
  4. Pfizer and Astellas’ Xtandi Achieve Primary Phase 3 Trial Goal for Prostate Cancer SubtypeLooking for Alpha
  5. Enzalutamide plus leuprolide improves MFS in non-metastatic castration-sensitive prostate cancerOncLive
  6. See full coverage on Google News

Leave a Comment

Your email address will not be published. Required fields are marked *